Futibatinib: First Approval.

Abstract

Futibatinib (Lytgobi®) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1-4 that is being developed by Taiho Oncology and Taiho Pharmaceutical for the treatment of cancers, including cholangiocarcinoma, breast cancer, gastric cancer, urothelial cancer, oesophageal cancer and non-small cell lung cancer. Futibatinib was approved in the USA on 30 September 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements. This article summarizes the milestones in the development of futibatinib leading to this first approval.

• Authors: Yahiya Y Syed
• Journal: Drugs (Drugs) Vol. 82 Issue 18 Pg. 1737-1743 (Dec 2022) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 36441501 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Receptor, Fibroblast Growth Factor, Type 2

Topics

• Adult
• Humans
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• Lung Neoplasms (genetics)
• Receptor, Fibroblast Growth Factor, Type 2
• Cholangiocarcinoma (metabolism)
• Bile Duct Neoplasms (genetics, metabolism, pathology)
• Bile Ducts, Intrahepatic (metabolism, pathology)